Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
A Small Biotech's Big Growth Spurt.
In: BusinessWeek, 2005-04-25, Heft 3930, S. 82-83
Online
serialPeriodical
Zugriff:
Reports on the success of Gilead Sciences Inc., a drug company specializing in HIV treatments. Death of HIV patients from kidney failure in clinical trials of Gilead's first drug, Preveon; Development of Viread, a safe drug for the treatment of HIV patients that generates $780 million in revenue for Gilead; Re-development of Preveon as Hepsera, a lower-dose of the drug used to treat hepatitis B; Gilead's position as having the third-largest market value among biotechnology companies; Hiring of Kevin Young to recruit salespeople and enter the European drug market.
Titel: |
A Small Biotech's Big Growth Spurt.
|
---|---|
Autor/in / Beteiligte Person: | Lacy, Sarah |
Link: | |
Zeitschrift: | BusinessWeek, 2005-04-25, Heft 3930, S. 82-83 |
Veröffentlichung: | 2005 |
Medientyp: | serialPeriodical |
ISSN: | 0007-7135 (print) |
Schlagwort: |
|
Sonstiges: |
|